Journal: Advanced Science
Article Title: Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives
doi: 10.1002/advs.202413786
Figure Lengend Snippet: Overview of psychedelic drugs and receptors in mental disorders. Psychedelic drugs, including psilocybin, MDMA, LSD, ketamine, ibogaine, and ayahuasca (DMT as an active component in ayahuasca brew), have renewed interest in treating psychiatric disorders. Emerging psychedelics are harnessed to restore symptoms against poor response rates to traditional medications, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive‒compulsive disorder, autism spectrum disorder (ASD), and substance use disorders (SUD) (e.g., alcohol and opioid). Some psychedelics interact collectively with diverse types or subtypes of receptors, and vice versa, owing to the structural similarities of cognate neurotransmitters. The psychedelics confer potentiation through their engaged receptors in a wide spectrum of improved outcomes. The interactive mechanism between psychedelics and receptors in response to mental disorders is still unclear and requires an explanation of which drugs are best suited to initiate a cascade. 5‐HTR: 5‐hydroxytryptamine receptor; AMPAR: α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; D1R: dopamine D1 receptor; TrkB: tropomyosin receptor kinase B; MDMA: N‐methyl‐3,4‐methylenedioxyamphetamine; LSD: lysergic acid diethylamide; NMDAR: N‐methyl‐D‐aspartate receptor. The figure was created with BioRender.com .
Article Snippet: ERK, D1R, and c‐fos , , 50 mg kg −1 , IP (Once a day for 7 d) , Male Sprague Dawley rats , Ketamine abuse model was established administration of ketamine IP injection. , Ketamine abusing enhanced the anxious behavior and disrupted NAc , [ ] .
Techniques: Medications